Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011 (2011), Article ID 621627, 8 pages
http://dx.doi.org/10.1155/2011/621627
Review Article

Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia

Unit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, Campus Bio-Medico University Hospital, Via Àlvaro del Portillo 200, 00128 Rome, Italy

Received 15 June 2011; Revised 23 August 2011; Accepted 6 September 2011

Academic Editor: Peter J. Quesenberry

Copyright © 2011 F. Marchesi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Zhang and J. D. Rowley, “Chromatin structural elements and chromosomal translocations in leukemia,” DNA Repair, vol. 5, no. 9-10, pp. 1282–1297, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. T. A. Milne, S. D. Briggs, H. W. Brock et al., “MLL targets SET domain methyltransferase activity to Hox gene promoters,” Molecular Cell, vol. 10, no. 5, pp. 1107–1117, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Hsieh, P. Ernst, H. Erdjument-Bromage, P. Tempst, and S. J. Korsmeyer, “Proteolitic cleavage of MLL generates a complex of N and C terminal fragments that confers protein stability and subnuclear localization,” Molecular and Cellular Biology, vol. 23, no. 1, pp. 186–194, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Schnittger, U. Kinkelin, C. Schoch et al., “Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML,” Leukemia, vol. 14, no. 5, pp. 796–804, 2000. View at Google Scholar · View at Scopus
  5. P. M. Ayton and M. L. Cleary, “Molecular mechanism of leukemogenesis mediated by MLL fusion proteins,” Oncogene, vol. 20, no. 40, pp. 5695–5707, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. E. Gillert, T. Leis, R. Repp et al., “DNA damage repair mechamism is involved in the origin of chromosomal translocation t(4;11) in primary leukemic cells,” Oncogene, vol. 18, no. 33, pp. 4663–4671, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. T. Burmeister, C. Meyer, S. Schwartz et al., “The MLL recombinone of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group,” Blood, vol. 113, no. 17, pp. 4011–4015, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. C. Meyer, E. Kowarz, J. Hofmann et al., “New insights to the MLL recombinome of acute leukemias,” Leukemia, vol. 23, no. 8, pp. 1490–1499, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. Kohlmann, C. Schoch, M. Dugas et al., “New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes,” Leukemia, vol. 19, no. 6, pp. 953–964, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. C. Monroe, S. Y. Jo, D. S. Sanders et al., “MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia,” Experimental Hematology, vol. 39, no. 1, pp. 77–86, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. E. Bitoun, P. L. Oliver, and K. E. Davies, “The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling,” Human Molecular Genetics, vol. 16, no. 1, pp. 92–106, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. C. Estable, M. H. Naghavi, H. Kato et al., “MCEF, the newest member of the AF4 family of transcription factors involved in leukemia, is a positive transcription elongation factor-b-associated protein,” Journal of Biomedical Science, vol. 9, no. 3, pp. 234–245, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Yokoyama, M. Lin, A. Naresh, I. Kitabayashi, and M. L. Cleary, “A higherorder complex containing AF4 and ENL family proteins with p-TEFb facilitates oncogenic and physologic MLL-dependent transcription,” Cancer Cell, vol. 17, no. 2, pp. 198–212, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. Benedikt, S. Baltruschat, B. Scholz et al., “The leukemogenic AF4–MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures,” Leukemia, vol. 25, no. 1, pp. 135–144, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. C. L. Dobson, A. J. Warren, R. Pannell, A. Forster, and T. H. Rabbitts, “Tumorigenesis in mice with a fusion of the leukaemia oncogene mll and the bacterial lacZ gene,” EMBO Journal, vol. 19, no. 5, pp. 843–851, 2000. View at Google Scholar · View at Scopus
  16. W. Chen, Q. Li, W. A. Hudson et al., “A murine MLL-AF9 knock-in model results in lymphoid and myeloid regulation and haematological malignancy,” Blood, vol. 108, no. 2, pp. 669–677, 2006. View at Google Scholar
  17. M. Metzler, A. Forster, R. Pannell et al., “A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology,” Oncogene, vol. 25, no. 22, pp. 3093–3103, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. V. Krivtsov, Z. Feng, M. E. Lemieux et al., “H3K79 methylation profiles define murine and human MLL-AF4 leukemias,” Cancer Cell, vol. 14, no. 5, pp. 355–368, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. Faber, A. V. Krivtsov, M. C. Stubbs et al., “Hoxa9 is required for survival in human MLL-rearranged acute leukemias,” Blood, vol. 113, no. 11, pp. 2375–2385, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. Kohlmann, C. Schoch, M. Dugas et al., “New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes,” Leukemia, vol. 19, no. 6, pp. 953–964, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. A. A. Ferrando, S. A. Armstrong, D. S. Neuberg et al., “Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation,” Blood, vol. 102, no. 1, pp. 262–268, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. D. Mueller, C. Bach, D. Zeisig et al., “A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification,” Blood, vol. 110, no. 13, pp. 4445–4454, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. E. Martin, T. A. Milne, S. Bloyer et al., “Dimerization of MLL fusion proteins immortalizes hematopoietic cells,” Cancer Cell, vol. 4, no. 3, pp. 197–207, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. J. L. Hess, C. B. Bittner, D. T. Zeisig et al., “c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells,” Blood, vol. 108, no. 1, pp. 297–304, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. A. Gessner, M. Thomas, P. Garrido Castro et al., “Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT,” Leukemia, vol. 24, no. 10, pp. 1751–1759, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. Y. Furuichi, K. Goi, T. Inukai et al., “Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents,” Cancer Research, vol. 67, no. 20, pp. 9852–9861, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. C. H. Pui, M. V. Relling, and J. R. Downing, “Acute lymphoblastic leukemia,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1535–1548, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. C. H. Pui, J. R. Kane, and W. M. Crist, “Biology and treatment of infant leukemias,” Leukemia, vol. 9, no. 5, pp. 762–769, 1995. View at Google Scholar · View at Scopus
  29. C. H. Pui, L. S. Frankel, A. J. Carroll et al., “Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases,” Blood, vol. 77, no. 3, pp. 440–445, 1991. View at Google Scholar · View at Scopus
  30. A. V. Moorman, C. J. Harrison, G. A. N. Buck et al., “Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial,” Blood, vol. 109, no. 8, pp. 3189–3197, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Mancini, D. Scappaticci, G. Cimino et al., “A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol,” Blood, vol. 105, no. 9, pp. 3434–3441, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. G. Cimino, L. Elia, M. Mancini et al., “Clinico-biologic features and treatment outcome in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome,” Blood, vol. 102, no. 6, pp. 2014–2020, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. W. D. Ludwig, H. Rieder, C. R. Bartram et al., “Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German Multicenter Trials GMALL 03/87 and 04/89,” Blood, vol. 92, no. 6, pp. 1898–1909, 1998. View at Google Scholar · View at Scopus
  34. F. Huguet, T. Leguay, E. Raffoux et al., “Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAAL-2003 study,” Journal of Clinical Oncology, vol. 27, no. 6, pp. 911–918, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. R. Bassan, O. Spinelli, E. Oldani et al., “Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL),” Blood, vol. 113, no. 18, pp. 4153–4162, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. J. M. Ribera, “Minimal residual disease-oriented treatment in Philadelphia chromosome-negative adult acute lymphoblastic leukemia,” Hematology Education: the Education Program for the Annual Congress of European Hematology Association, vol. 4, pp. 6–12, 2010. View at Google Scholar
  37. J. M. Rowe and C. Ganzel, “Management of acute lymphoblastic leukemia in adults,” Hematology Education: the Education Program for the Annual Congress of European Hematology Association, vol. 5, pp. 9–19, 2011. View at Google Scholar
  38. N. Vey, X. Thomas, C. Picard et al., “Allogeneic stem cell transplantation improves the outcome of adult with t(1;19)/EA2-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of prospective multicenter LALA-94 study,” Leukemia, vol. 20, no. 12, pp. 2155–2161, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. J. M. Ribera, A. Oriol, C. Bethencourt et al., “Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial,” Haematologica, vol. 90, no. 10, pp. 1346–1356, 2005. View at Google Scholar
  40. W. D. Ludwig, A. Raghavachar, and F. Thiel, “Immunophenotypic classification of acute lymphoblastic leukemia,” Bailliere's Clinical Haematology, vol. 7, no. 2, pp. 235–262, 1994. View at Publisher · View at Google Scholar
  41. M. C. Béné, G. Castoldi, W. Knapp, European Group for the Immunological Characterization of Leukemias (EGIL) et al., “Proposals for the immunological classification of acute leukemias,” Leukemia, vol. 9, no. 10, pp. 1783–1786, 1995. View at Google Scholar
  42. J. E. Rubnitz, F. G. Behm, and J. R. Downing, “11q23 rearrangements in acute leukemia,” Leukemia, vol. 10, no. 1, pp. 74–82, 1996. View at Google Scholar
  43. S. Schwartz, H. Rieder, B. Schläger, T. Burmeister, L. Fischer, and E. Thiel, “Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype,” Leukemia, vol. 17, no. 8, pp. 1589–1595, 2003. View at Publisher · View at Google Scholar · View at PubMed
  44. A. Reiter, M. Schrappe, W. D. Ludwig et al., “Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicentric trial ALL-BFM86,” Blood, vol. 84, no. 9, pp. 3122–3133, 1994. View at Google Scholar
  45. G. Cimino, N. Cenfra, L. Elia et al., “The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience,” Haematologica, vol. 95, no. 5, pp. 837–840, 2010. View at Publisher · View at Google Scholar · View at PubMed
  46. A. T. Look, “Oncogenic transcription factors in the human acute leukemias,” Science, vol. 278, no. 5340, pp. 1059–1064, 1997. View at Publisher · View at Google Scholar
  47. D. G. Gilliland and M. S. Tallman, “Focus on acute leukemias,” Cancer Cell, vol. 1, no. 5, pp. 417–420, 2002. View at Publisher · View at Google Scholar
  48. G. Cimino, F. Lo Coco, A. Biondi et al., “ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy,” Blood, vol. 82, no. 2, pp. 544–546, 1993. View at Google Scholar
  49. C. Meyer, B. Schneider, S. Jakob et al., “The MLL recombinome of acute leukemias,” Leukemia, vol. 20, no. 5, pp. 777–784, 2006. View at Publisher · View at Google Scholar · View at PubMed
  50. A. H. Goldstone, S. M. Richards, H. M. Lazarus et al., “In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993),” Blood, vol. 111, no. 4, pp. 1827–1833, 2008. View at Publisher · View at Google Scholar · View at PubMed
  51. D. I. Marks, W. S. Perez, W. He et al., “Unrelated donor transplants in adult with Philadelphia-negative acute lymphoblastic leukemia,” Blood, vol. 112, no. 2, pp. 426–434, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. P. Ljungman, M. Bregni, M. Brune et al., “Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009,” Bone Marrow Transplantation, vol. 45, no. 2, pp. 219–234, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. J. Gabert, E. Beillard, V. H. J. van der Velden et al., “Standardization and quality control studies of 'real time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer Program,” Leukemia, vol. 17, no. 12, pp. 2318–2357, 2003. View at Publisher · View at Google Scholar · View at PubMed
  54. F. Y. Mortuza, M. Papaioannou, I. M. Moreira et al., “Minimal residual disease tests provide an independent factor of clinical outcome in adult acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 20, no. 4, pp. 1094–1104, 2002. View at Publisher · View at Google Scholar
  55. M. Bruggemann, T. Raff, T. Flohr et al., “Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia,” Blood, vol. 107, no. 3, pp. 1116–1123, 2006. View at Publisher · View at Google Scholar · View at PubMed
  56. G. Cimino, L. Elia, M. C. Rapanotti et al., “A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia,” Blood, vol. 95, no. 1, pp. 96–101, 2000. View at Google Scholar
  57. R. Bassan and D. Hoelzer, “Modern therapy of acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 29, no. 5, pp. 532–543, 2011. View at Google Scholar